; Aarkstore.com - Antibiotics and Drug Resistance 2008
Learning Center
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Aarkstore.com - Antibiotics and Drug Resistance 2008


  • pg 1
									Aarkstore.com announces, a new market research report is available in its vast collection:

                      Antibiotics and Drug Resistance 2008

New drug innovation and the strategy to combat antibiotic resistance mechanisms

Introduction: This report reviews new drug innovation and strategy to combat antibiotic resistance
mechanisms. This embraces current research-stage activities, patents published in the last five years,
the entire pharmaceutical development pipeline and todays existing armoury of anti-bacterial drugs.
The report reviews around 400+ pipeline antibiotics and anti-bacterial technologies (from pre-clinical
to Phase III/initial launch), 350+ antibiotic patents published between Jan 2002 and Jan 2008 and
more than 200 fully launched antibiotics. It identifies and discusses new antibiotics, technologies and
strategies at the anti-bacterial mechanistic level, that are specifically being developed to combat
resistance mechanisms. The opportunities which they potentially offer in tackling the increasing global
threat of antibiotic resistance, are discussed.

Overview: This report gives a comprehensive and detailed review of pipeline, emerging and current
antibiotics and anti-bacterial technologies and their potential to provide more effective long-term
therapies. More than 900 drugs, drug candidates and developmental compounds are identified,
discussed and classified on the basis of their mode of action, developmental stage, activities and
capabilities and by companies and research groups responsible for taking these activities forward.
Moreover, they are considered in terms of their importance and potential to combat resistant
pathogens, as part of the global effort to find alternatives to current antibiotics, which have lost or are
losing their effectiveness against common and serious pathogens. The report looks in depth at current
developments and thinking on how antibiotic resistance can be tackled technically and strategically,
from improvements to existing drugs and drug combinations, to novel molecules, new and more
promising drug targets and approaches to tackling resistance at its source. More detailed information
on this report is given in the printable Report Description, which is linked to this page. Combating
Antibiotic Resistance: This review examines more than 370 pipeline candidates and 340 antibiotic
patents, published between Jan 2002 and Jan 2008. These patents were selected from more than
1800 patents citing “anti-infectives”, published over the same period. Strategies being developed to
combat resistance mechanisms include the identification of new selective targets, the selection of
targets which may preclude genomic/phenotypic adaptation by bacteria, or where this is considered
more difficult, combined activity molecules, molecules which inhibit stress-induced mutational
emergence of resistance genes in response to synthetic antibiotics, novel antibacterial technologies,
new targeting strategies and synthetic or semi-synthetic approaches vs. drugs of natural origin. Other
areas reviewed include virulence targeting, the dissemination of adaptable traits, predicting resistance
and the developing importance of pathogenomics.

Table of Contents:

Executive Summary 9

1.1 Background
1.2 Antibiotic Resistance
1.3 Resistance Mechanisms
1.4 The Resistome
1.5 Pathogenomics
1.6 Antibiotics, Strategies and Targets
1.7 The Cost of Antibiotic Resistance
1.8 Global Surveillance
1.9 This Report

2.1 Antibiotic Resistance
2.2 Europe
2.2.1 Escherichia coli
2.2.2 Streptococcus pneumoniae
2.2.3 Staphylococcus aureus
2.2.4 Enterococci
2.2.5 Klebsiella pneumoniae
2.2.6 Pseudomonas aeruginosa
2.3 England and Wales
2.3.1 Gram-positive cocci
2.3.2 Gram-negative bacilli
2.3.3 Other pathogens
2.4 Other countries
2.5 China
2.6 USA
2.7 Kuwait
2.8 Discussion

3.1 Current Anti-Infectives
3.2. Anti-bacterials
3.3 Bacterial Cell Wall Inhibitors
3.4 Immune Stimulators
3.5 30S/50S Ribosomal Subunit Inhibitors Page
3.6 DNA Gyrase/Topoisomerase Inhibitors
3.7 Other Antibiotics
3.8 Discussion

More Related Reports :

 Biomarkers in Parkinsons Disease, 2011

 Biomarkers in Breast Cancer, 2011

 Stroke: Competing Treatments and Market Entry Considerations

 Neuropathic Pain: Competing Treatments and Market Entry Considerations

 Hypertension: Competing Treatments and Market Entry Considerations

 Alzheimers Disease: Competing Treatments and Market Entry Considerations

 Targeting Cancer Stem Cells: Therapeutic Strategies, Pipeline, Biomarkers and Opportunities

  Peripheral Neuropathy and Neuropathic Pain, 2008: Current, pipeline and emerging drugs for the
treatment of peripheral neuropathy and neuropathic pain
 Alzheimers Disease: Markets, Pipeline and Opportunities 2009

 Cancer Drug Resistance

 Antibiotics and Drug Resistance 2008

For More details about above & other Reports plz contact :



Contact: Marketing team


Email: enquiry@aarkstore.com

URL: http://www.aarkstore.com/




To top